Abstract 628
Background
Metastasectomy is hypothesised to improve overall survival (OS) in patients with metachronous metastasis of STS. Evidence in favour of this approach comes from non-controlled single-arm studies subjected to selection bias. In the present study, advanced comparative effectiveness methods were used to assess the efficacy of metastasectomy vs. “non-invasive” treatments (i.e. chemotherapy, radiotherapy, best supportive care) in patients with metachronous STS-metastasis.
Methods
135 patients with metachronous STS metastasis, selected out of a population of over 1000 STS patients, who had primarily undergone surgery for localised STS between 1998 and 2015 at two tertiary tumour centres were retrospectively included. In order to evaluate the efficacy of metastasectomy on OS, a propensity score (PS) was estimated, including variables at time of treatment decision for metastatic disease (“baseline”). Based on the PS, an inverse-probability-of-treatment-weight (IPTW) model was calculated to allow analyses with adjustment for favourable prognostic factors prevailing in patients undergoing metastasectomy (for metastasectomy: IPTW=1/PS; for “non-invasive” treatment: IPTW=1/(1-PS)).
Results
OS was significantly better in those 68 patients (44.4%) who had undergone metastasectomy (10-year OS: 23% vs. 4%; log-rank test: p < 0.0001; hazard ratio (HR): 0.34, 95% confidence interval (CI): 0.22-0.53, p < 0.0001). This positive association prevailed after recalculation of time-to-event-analyses with IPTW-weighted data ((adjusted 10-year OS: 17% vs. 3%, log-rank-test: p < 0.0001; HR: 0.33, 95%CI: 0.20-0.52, p < 0.0001), compensating for positive prognostic factors prevailing in patients with metastasectomy (i.e. smaller number of metastases, better ECOG performance status, better haemoglobin- and albumin-levels).
Conclusions
In the present bi-centre study, metastasectomy was associated with a significant benefit on OS, persisting even after adjustment for favourable prognostic factors prevailing in patients undergoing metastasectomy. Our data indicate that metastasectomy should be considered as first choice in patients with metachronous metastasis of STS.
Clinical trial identification
Legal entity responsible for the study
Medical University of Graz.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract